Information Provided By:
Fly News Breaks for February 8, 2018
IOVA
Feb 8, 2018 | 07:15 EDT
Iovance Biotherapeutics is "traveling toward acquisition," and a takeout could even happen before the end of 2018, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note. The analyst views melanoma as the "low hanging fruit" of getting TILs to market, but sees a "growing clinical database in additional solid tumors as the game changing thesis." TILs are showing themselves to be significantly safer than CAR-T therapy, the analyst adds. He believes Iovance's LN-145 may represent a more efficacious therapy for solid tumor indications in earlier settings as well. The analyst keeps a Buy rating on the shares with a $22 price target.
News For IOVA From the Last 2 Days
There are no results for your query IOVA